An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction

Nature Reviews Urology

Volumn 7, Issue 11, 2010, Pages 603-609

  Palit, Victor ^a   Eardley, Ian ^b  

^a UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVANAFIL; BREMELANOTIDE; CALCITONIN GENE RELATED PEPTIDE; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LODENAFIL CARBONATE; MELANOCORTIN RECEPTOR AGONIST; MIRODENAFIL; NAKED DNA; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PLACEBO; PLASMID DNA; SILDENAFIL; SLX 2101; SUPEROXIDE DISMUTASE; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VASCULOTROPIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABSENCE OF SIDE EFFECTS; BACKACHE; CLINICAL TRIAL; COLOR VISION; COLOR VISION DEFECT; CONJUNCTIVAL HYPEREMIA; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; EYE DISEASE; EYE REDNESS; FOOD AND DRUG ADMINISTRATION; GENE THERAPY; GENE TRANSFER; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; IC 50; INDIGESTION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NERVOUS SYSTEM INJURY; NOSE CONGESTION; PENIS ERECTION; PENIS PROSTHESIS; PRIORITY JOURNAL; PROSTATECTOMY; RECOMMENDED DRUG DOSE; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VACUUM; VASCULAR DISEASE; VIRAL GENE THERAPY; VISUAL DISORDER; VITAL SIGN; VOMITING;

ADMINISTRATION, ORAL; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 78549285356     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.165     Document Type: Review

References (44)

1. Corbin, J. D. & Francis, S. H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 274, 13729-13732 (1999).
2. Corbin, J. D. & Francis, S. H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 56, 453-459 (2002).
3. Eardley, I. et al. Pharmacotherapy for erectile dysfunction. J. Sex. Med. 7 (1 Pt 2), 524-540 (2010).
4. Porst, H. et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 62, 121-125 (2003).
5. Kim, B. H. et al. Safety, tolerability, and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br. J. Clin. Pharmacol. 65, 848-854 (2008).
6. Prince, W. et al. SLx-2102, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J. Urol. 175 (Suppl. 4), 924 (2006).
7. Moncada, I., Jara, J., Subirá, D., Castaño, I. & Hernández, C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur. Urol. 46, 357-360 (2004).
8. Porst, H. et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur. Urol. 50, 351-359 (2006).
9. Rajfer, J. et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double blind, placebo-controlled study in the US. Int. J. Impot. Res. 19, 95-103 (2007).
10. Porst, H. et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J. Sex. Med. 5, 2160-2169 (2008).
11. Eardley, I. et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int. 96, 1323-1332 (2005).
12. Tolrà, J. R., Campaña, J. M., Ciutat, L. F. & Miranda, E. F. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J. Sex. Med. 3, 901-909 (2006).
13. Rubio-Aurioles, E. et al. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J. Sex. Med. 3, 1037-1049 (2006).
14. DOh, H. et al. Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch. Pharm. Res. 25, 873-878 (2002)
15. Paick, J. S. et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J. Sex. Med. 5, 946-953 (2008).
16. Park, N. C., Min, K. S. & Paick, J. S. Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized controlled trial [abstract PS-02-013]. J. Sex. Med. 3 (Suppl. 3), 180 (2006).
17. Kim, J. J. Efficacy and safety of fixed-dose Udenafil (Zydena®) in men with diabetes and erectile dysfunction [abstract P-06-056]. J. Sex. Med. 5 (Suppl. 2); 63(2008).
18. Kangwon, K. et al. The efficacy and safety of once-a-day dosing of udenafil in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study [abstract PD-056]. J. Sex. Med. 6 (Suppl. 2), 65 (2009).
19. Lee, H. S. et al. Identification of cytochrome P450 enzymes responsible for N-dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica 38, 21-33 (2008).
20. Paick, J. S. et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J. Sex. Med. 5, 2672-2680 (2008).
21. Park, N. C. et al. Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in men with diabetes: a multi-center, randomized, double blind, placebo-controlled, fixed dose, parallel group clinical trial [abstract 370]. Eur. Urol. Suppl. 8, 213 (2009).
22. Toque, H. A. et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur. J. Pharmacol. 591, 189-195 (2008).
23. Glina, S. et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J. Sex. Med. 6, 553-557 (2009).
24. Kaufman, J. & Dietrich, J. Safety and efficacy of avanafil, a new PDE5 inhibitor for treating erectile dysfunction [abstract 923]. J. Urol. 175 (Suppl. 4), 299 (2006).
25. Sweetnam, P. et al. SLx-2101, a novel long-acting phosphodiesterase-5 (PDE5) inhibitor for erectile dysfunction: in vivo and in vitro studies [abstract 51]. J. Sex. Med. 3 (Suppl. 1), 30 (2006).
26. Donabedian, D. et al. SLx-2101, a new long-acting PDE5 inhibitor: preliminary safety, tolerability, PK and endothelial function effects in healthy subjects [abstract MP-03-102]. J. Sex. Med. 3 (Suppl. 3), 209 (2006).
27. Van der Ploeg, L. H. et al. A role for the melanocortin 4 receptor in sexual function. Proc. Natl Acad. Sci. USA 99, 11381-11386 (2002).
28. Rosen, R. C., Diamond, L. E., Earle, D. C., Shadiack, A. M. & Molinoff, P. B. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int. J. Impot. Res. 16, 135-142 (2004).
29. KAminetsky, J. et al. Phase IIB study of bremelanotide in the treatment of ED in non-diabetic males [abstract 1042]. J. Urol. 177 (4 Suppl.), 345 (2007).
30. Steidle, C. P. et al. Phase IIB study of bremelanotide in the treatment of ED in diabetic males [abstract 1177]. J. Urol. 177 (4 Suppl.), 388 (2007).
31. Christ, G. J. & Melman, A. The application of gene therapy to the treatment of erectile dysfunction. Int. J. Impot. Res. 10, 111-112 (1998).
32. Kendirci, M., Teloken, P. E., Champion, H. C., Hellstrom, W. J. & Bivalacqua, T. J. Gene therapy for erectile dysfunction: fact or fiction? Eur. Urol. 50, 1208-1222 (2006).
33. Melman, A., Bar-Chama, N., McCullough, A., Davies, K. & Christ, G. Plasmid based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial. Isr. Med. Assoc. J. 9, 143-146 (2007).
34. Melman, A., Bar-Chama, N., McCullough, A., Davies, K. & Christ, G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum. Gene Ther. 17, 1165-1176 (2006).
35. Gholami, S. S. et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J. Urol. 169, 1577-1581 (2003).
36. Rogers, R. S., Graziottin, T. M., Lin, C. S., Kan, Y. W. & Lue, T. F. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int. J. Impot. Res. 15, 26-37 (2003).
37. Liu, W. J. et al. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J. Androl. 7, 381-388 (2005).
38. Eng, W. et al. Superoxide dismutase\a target for gene therapeutic approach to reduce oxidative stress in erectile dysfunction. Methods Mol. 610, 213-227 (2010).
39. Azadzoi, K. M., Golabek, T., Radisavljevic, Z. M., Yalla, S. V. & Siroky, M. B. Oxidative stress and neurodegeneration in penile ischaemia. BJU Int. 105, 404-410 (2009).
40. Shen, Z. J. et al. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int. 95, 890-894 (2005).
41. Bivalacqua, T. J., Champion, H. C., Abdel-Mageed, A. B., Kadowitz, P. J. & Hellstrom, W. J. Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol. Reprod. 65, 1371-1377 (2001).
42. Gonzalez-Cadavid, N. F. & Rajfer, J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp. Gerontol. 39, 1705-1712 (2004).
43. Bivalacqua, T. J. et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292, H1278-H1290 (2007).
44. Nolazco, G. et al. Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int. 101, 1156-1164 (2008).